Online citations, reference lists, and bibliographies.
← Back to Search

Therapeutic Outcome According To Histologic Subtype In 121 Patients With Malignant Pleural Mesothelioma.

G. Ceresoli, L. Locati, A. J. Ferreri, C. Cozzarini, P. Passoni, G. Melloni, P. Zannini, A. Bolognesi, E. Villa
Published 2001 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
One-hundred and twenty-one cases of malignant pleural mesothelioma (MPM) seen between 1986 and 1999 at the authors' Institution were reviewed. Histotype was epithelial in 88 patients (73%), sarcomatous in 21 (17%) and mixed in 12 (10%). Ninety-one patients received a treatment (38 palliative pleurectomy and no further therapy, 16 palliative pleurectomy followed by chemotherapy, 37 chemotherapy alone), while 30 were referred to supportive care only. Median survival of the whole population was 10.5 months. The 1-, 2- and 3-year survival were 40, 17 and 8%, respectively. Univariate analysis of subgroups showed that poor performance status (PS), non-epithelial histotype, Butchart stage>I and International Mesothelioma Interest Group (IMIG) stage>I were individually associated with lower survival. Patients receiving any therapy survived longer than patients treated with supportive care only (P=0.0004). Treatment modality had an independent prognostic value (P=0.00005), with a survival advantage for patients receiving surgery and adjuvant chemotherapy. Multivariate analysis confirmed the independent prognostic value of PS (P=0.001; HR=2.48) and treatment modality (P=0.003; HR=1.38). The prognostic role of PS (P=0.02) and treatment modality (P=0.01) was confirmed in the subset of patients with epithelial histology. On the contrary, therapy had no impact on survival in patients with sarcomatoid MPM (P=0.74). Despite the predicted bias of a retrospective non-randomized evaluation of treatment-related factors, patients with good PS and epithelial histology seemed to have a survival benefit from surgery or multimodality therapy, as opposite to patients with poor PS or non-epithelial histotype. However, these results must be confirmed in a larger prospective trial with uniform treatment.
This paper references
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1378/CHEST.93.1.159
Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients.
E. Chailleux (1988)
10.1002/IJC.2910410409
Survival patterns for malignant mesothelioma: The seer experience
R. Spirtas (1988)
10.7326/0003-4819-96-6-746
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.
A. Chahinian (1982)
10.1046/j.1365-2559.1997.5460776.x
Pathology of malignant mesothelioma
R. Attanoos (1997)
10.1007/978-1-4612-4380-9_37
Regression Models and Life-Tables
D. Cox (1972)
10.1002/1097-0142(19930715)72:2<389::AID-CNCR2820720213>3.0.CO;2-V
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis
C. Boutin (1993)
10.1200/JCO.1989.7.8.1157
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.
P. Ruffié (1989)
10.1378/CHEST.116.2.504
Advances in the treatment of malignant pleural mesothelioma.
D. Sterman (1999)
10.1016/S0140-6736(95)90462-X
Continuing increase in mesothelioma mortality in Britain
J. Peto (1995)
10.1016/S1010-7940(00)00377-8
18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.
A. Carretta (2000)
10.1634/THEONCOLOGIST.4-6-488
Contemporary management of malignant pleural mesothelioma.
E. Butchart (1999)
10.1378/CHEST.109.1.109
Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas.
L. Johansson (1996)
10.1002/1097-0142(19930715)72:2<410::AID-CNCR2820720216>3.0.CO;2-G
Prognostic factors of malignant mesothelioma of the pleura.
A. Anand (1994)
10.1016/S0003-4975(99)01038-3
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.
V. Rusch (1999)
Prognostic factors and survival in malignant pleural mesothelioma.
T. van Gelder (1994)
10.1159/000196043
Diagnosis and prognostic factors in malignant pleural mesothelioma: a retrospective analysis of sixty-five patients.
L. Tammilehto (1992)
10.1016/0169-5002(92)90005-5
Malignant mesothelioma: prognostic factors in a prospective study of 98 patients
L. Tammilehto (1992)
10.1016/S0169-5002(00)00152-5
Surgical approach to pleural diffuse mesothelioma in Japan.
K. Takagi (2001)
10.1200/JCO.1988.6.3.527
Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.
A. Alberts (1988)
10.1007/978-1-4612-4380-9_25
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
Evaluation of survival data and two new rank order statistics arising in its consideration.
N. Mantel (1966)
10.1093/ANNONC/8.SUPPL_1.S139
The emerging role of immunotoxins in leukemia and lymphoma.
U. Winkler (1997)
10.1136/thorax.55.9.731
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
[Prognostic factors in diffuse malignant mesothelioma of the pleura].
J. Schildge (1989)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
10.1183/09031936.98.12040972
Malignant pleural mesothelioma.
C. Boutin (1998)
10.1200/JCO.1988.6.1.147
Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985.
K. Antman (1988)
10.1002/1097-0142(19930715)72:2<394::AID-CNCR2820720214>3.0.CO;2-5
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging
C. Boutin (1993)
10.1016/0169-5002(94)90804-4
Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients.
V. Fusco (1993)



This paper is referenced by
10.5606/tgkdc.dergisi.2016.11606
Epithelial membrane antigen in differential diagnosis of malignant mesothelioma, metastatic adenocarcinoma, and reactive mesothelial hyperplasia Malign mezotelyoma, metastatik adenokarsinoma ve reaktif mezotelyal hiperplazi ayirici tanisinda epitelyal membran antijeni
Sibel Arslan (2016)
10.1097/MCP.0b013e328354acfe
Asbestos-related pleural disease
R. Myers (2012)
10.1016/j.cllc.2017.01.008
The Controlling Nutritional Status Score Is a Significant Independent Predictor of Poor Prognosis in Patients With Malignant Pleural Mesothelioma
Shinkichi Takamori (2017)
10.1007/978-3-642-10862-4_7
Surgical therapy of mesothelioma.
D. Rice (2011)
10.1007/s12253-016-0181-3
Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis
T. Plönes (2016)
10.1007/s12253-013-9677-2
BAP1 Protein is a Progression Factor in Malignant Pleural Mesothelioma
L. Arzt (2013)
Advances in diagnosis and treatment of malignant mesothelioma
J.P.J.J. Hegmans (2006)
10.5761/ATCS.OA.10.01572
Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience.
T. Yan (2011)
Ifosfamide, carboplatin and etoposide combined with 41.8 degrees C whole body hyperthermia for malignant pleural mesothelioma.
A. Bakhshandeh (2003)
10.1097/JTO.0b013e318070ccaf
State of the Art: Pleuroscopy
P. Lee (2007)
10.1371/journal.pone.0181114
Apoptosis by [Pt(O,O′-acac)(γ-acac)(DMS)] requires PKC-δ mediated p53 activation in malignant pleural mesothelioma
A. Muscella (2017)
10.1016/S0169-5002(02)00536-6
Ifosfamide, carboplatin and etoposide combined with 41.8 °C whole body hyperthermia for malignant pleural mesothelioma
A. Bakhshandeh (2003)
10.1371/journal.pone.0065903
Variation in Drug Sensitivity of Malignant Mesothelioma Cell Lines with Substantial Effects of Selenite and Bortezomib, Highlights Need for Individualized Therapy
Adam Szulkin (2013)
Characterization of malignant pleural mesothelioma : possibilities for an individualized therapeutic arsenal
Adam Szulkin (2014)
10.1007/s11912-011-0177-9
Malignant Pleural Mesothelioma
S. Raja (2011)
10.3892/IJO_00000675
Establishment of in vivo fluorescence imaging in mouse models of malignant mesothelioma.
Norie Yamaoka (2010)
10.1111/j.1440-1843.2005.00737.x
Rigid and semirigid pleuroscopy: The future is bright
P. Lee (2005)
10.1159/000102867
Diagnostik und Therapie des Pleuramesothelioms*
K. Junker (2007)
10.3978/j.issn.2218-6751.2014.07.01
The role of interleukin-6 in malignant mesothelioma.
S. N. Abdul Rahim (2015)
10.3389/fonc.2013.00203
Microenvironment-Dependent Phenotypic Changes in a SCID Mouse Model for Malignant Mesothelioma
E. Darai-Ramqvist (2013)
Malignant pleural mesothelioma : novel biomarkers and related pathways
Filip Mundt (2013)
10.1080/02841860701754182
Prevention of malignant seeding at drain sites after invasive procedures (surgery and/or thoracoscopy) by hypofractionated radiotherapy in patients with pleural mesothelioma
M. Di Salvo (2008)
10.1186/s12967-020-02487-6
Tissue expression of lactate transporters (MCT1 and MCT4) and prognosis of malignant pleural mesothelioma (brief report)
Irene Dell'Anno (2020)
10.1016/J.HOC.2006.01.021
The role of radiation therapy in thoracic tumors.
F. Kong (2006)
10.1053/J.OPTECHSTCVS.2006.02.002
Treatment of Malignant Pleural Mesothelioma: Pleurectomy with Adjuvant Therapy
R. Flores (2006)
10.1023/B:SUPE.0000014815.98056.f6
Contributing authors
S. Devadas (2004)
10.1200/JCO.2005.07.050
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
D. Fennell (2005)
HMGB-1 Release and the CD8+ T Cell Response Elicited by Radiation Treatment in Malignant Pleural Mesothelioma
Matthew Wu (2015)
10.1016/j.ctrv.2010.11.004
Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?
V. Agarwal (2011)
10.1097/00001622-200303000-00002
Predictive and prognostic factors in malignant pleural mesothelioma
P. Baas (2003)
A case of diffuse pleural mesothelioma in which contralateral exploratory thoracoscopy assisted the selection of therapy.
A. Yamazaki (2005)
10.1097/MAJ.0b013e318039c7d1
A Large Abdominal Wall Mass as an Initial Manifestation of Malignant Mesothelioma
T. Takeda (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar